Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well-tolerated safety profile over 12 months across two Phase 3 trials.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bristol-Myers Squibb (BMY – Research Report) and Envista ...

Bristol Myers Squibb Q3 revenue rose 8% YoY to $11.89 billion, driven by strong Growth Portfolio sales, especially Eliquis.

Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...

Bristol-Myers Squibb Co.’s stock rose 2.9% early Thursday, after the drug company posted better-than-expected third-quarter earnings and raised its guidance. Princeton, N.J.-based Bristol Myers had ...

Reports Q3 revenue $11.89B, consensus $11.28B. “We made important strides in the third quarter with the landmark U.S. approval of ...

The Coventry Police Department said a dog owner requested that their dog be killed because it had an aggressive temperament. It happened on Oct. 24. Investigators arrested Anthony Demitraszek as a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term ...